sorafenib has been researched along with salvin in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (salvin) | Trials (salvin) | Recent Studies (post-2010) (salvin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 396 | 1 | 291 |
| Protein | Taxonomy | sorafenib (IC50) | salvin (IC50) |
|---|---|---|---|
| B-cell CLL/lymphoma 9 protein | Homo sapiens (human) | 5.213 | |
| Prostaglandin E synthase | Homo sapiens (human) | 5 | |
| Catenin beta-1 | Homo sapiens (human) | 5.213 | |
| Protease | Human immunodeficiency virus 1 | 0.24 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, C; Luna, A; Pham, K; Studzinski, GP; Wang, X; Wu, Q | 1 |
1 other study(ies) available for sorafenib and salvin
| Article | Year |
|---|---|
Enhancement of sorafenib-mediated death of Hepatocellular carcinoma cells by Carnosic acid and Vitamin D2 analog combination.
Topics: Abietanes; Antineoplastic Agents; Antioxidants; Apoptosis; Autophagy; Bone Density Conservation Agents; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Ergocalciferols; Humans; Liver Neoplasms; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2020 |